Myriad Genetics (MYGN) is well poised for growth in the coming quarters, backed by strong improvement in testing volume across all its businesses. Strong solvency is an added advantage. Yet, foreign exchange headwinds and stiff competition are a concern.In the past six months, this Zacks Rank #3 (Hold) stock has gained 32.8% compared with a 0.6% rise of the industry and a 20% rise of the S&P 500 composite.The renowned genetic testing and precision medicine company has a market capitalization of $1.83 billio ...